The Rising Tide of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Synthesis of Medication Eligibility and Clinical Implementation

MedXY Editorial Team•Mar 18, 2026•Cardiology

Up to 61% of US adults (approximately 148 million) meet FDA-approved indications for at least one of three novel CKM therapy classes: GLP-1RAs, SGLT2is, or nsMRAs.
GLP-1 receptor agonist eligibility is the most prevalent, encompassing over 50% of the population, driven largely by expanded indications for obesity and cardiovascular risk reduction.
Nearly 12 million adults qualify for ‘triple therapy’ (all three medication classes), signifying a complex population with multi-organ risk profiles.
Significant disparities in eligibility exist between general population surveys and ambulatory healthcare samples, highlighting a massive ‘implementation gap’ in clinical practice.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Up to 61% of US adults (approximately 148 million) meet FDA-approved indications for at least one of three novel CKM therapy classes: GLP-1RAs, SGLT2is, or nsMRAs.
GLP-1 receptor agonist eligibility is the most prevalent, encompassing over 50% of the population, driven largely by expanded indications for obesity and cardiovascular risk reduction.
Nearly 12 million adults qualify for ‘triple therapy’ (all three medication classes), signifying a complex population with multi-organ risk profiles.
Significant disparities in eligibility exist between general population surveys and ambulatory healthcare samples, highlighting a massive ‘implementation gap’ in clinical practice.